Encouraging HOT Study Results

7 July 1996

Hypertension Patients Still Undertreated

Despite the wide range of antihypertensive drugs currently on the market and being utilized by the patient population, the risk of cardiovascular disease and stroke is still much greater in hypertensives compared to normotensive patients, reported Astra at the 16th International Society of Hypertension meeting held in Glasgow, Scotland on June 23.

Over half of the patients receiving treatment for hypertension fail to reach the blood pressure levels set out in national and international guidelines, ie a diastolic pressure of less than 90 mmHg. This puts them at a much higher risk of fatal or nonfatal cardiac events.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight